On Wednesday, Shares of Sprint Corporation (NYSE:S), lost -4% to $3.84.
On July 2, Sprint Corporation, and Dixons Carphone declared a commercial relationship that pairs Sprint with a premier European consumer electronics retailer renowned for innovation in wireless retail sales. The relationship is predictable to accelerate Sprint’s retail transformation, and is the latest inventive move to grow its number of retail stores.
As part of the arrangement, in coming months Sprint will work closely with Dixons Carphone Connected World Services (CWS) division on a pilot program to build and operate about 20 new Sprint stores in select U.S. markets. These Sprint stores will operate similarly to the third-party retailers who operate Sprint-branded wireless stores across the U.S. Sprint will own and staff the stores while CWS will manage them. CWS will also apply its expertise and best practices across all of Sprint’s sales channels.
This agreement is the latest in Sprint’s strategy to expand its distribution and provide shoppers with a better customer experience. Earlier this year, Sprint quickly and cost-effectively doubled the number of corporate-owned stores by opening Sprint at RadioShack in 1,435 locations, which are presently undergoing renovation. Sprint has also launched Direct 2 You, a one-of-a-kind service that brings a personalized sales experience directly to customers whenever and wherever they want – for free.
Sprint Corporation, through its auxiliaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. Virgin Islands.
Shares of Synthetic Biologics Inc. (NYSEMKT:SYN), declined -6% to $3.76, during its last trading session, hitting its highest level.
Synthetics Biologics, declared that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Synthetic Biologics. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the share amount sold to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be accomplished, or as to the actual size or terms of the offering.
William Blair & Company, L.L.C. and RBC Capital Markets, L.L.C. are the joint book-running managers for the offering. BTIG, L.L.C. is serving as co-manager for the offering.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis.
Finally, Silver Wheaton Corp. (NYSE:SLW), ended its last trade with -2.96% loss, and closed at $14.40, hitting its lowest level.
Silver Wheaton Corp., will release 2015 second quarter results on Tuesday, August 11, 2015, after market close.
A conference call will be held Wednesday, August 12, 2015, starting at 11:00 am (Eastern Time) to talk about these results.
Silver Wheaton Corp. operates as a precious metals streaming company worldwide. The company has 18 long-term purchase agreements and 1 early deposit long-term purchase agreement associated with silver and gold regarding27 various mining assets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
